The systolic reduction from semaglutide contributed to a 20% reduction in major cardiovascular events
Semaglutide (brand names Wegovy for obesity, Ozempic for diabetes) produces 12-15 percent body weight reduction in clinical trials
More on weight and health Is Fatty15 worth the hype
As part of their agreements with CMS, the manufacturers must demonstrate how these lifestyle support programs will meet the program requirements, including encouraging healthy eating and increasing physical activity, supporting medication adherence, ensuring engagement with the program on a regular basis, and ensuring availability of this program to all patients receiving these medications, either online or offline for those who have limited digital access
Six of the letters sent to outsourcing facilities include a recommendation to engage a third-party consultant with relevant sterile drug manufacturing expertise to assist with a comprehensive evaluation that includes review of aseptic processing techniques
Some people also reported that they stopped taking the drug expressly because they were worried about perceived excessive weight loss, according to the company